VIVUS price target lowered to $17 from $20 at Leerink Leerink lowered its price target for VIVUS citing softer than expected Qsymia Scripts after the company issued an update yesterday. Leerink notes that actual Q3 Qsymia scripts grew 33% quarter over quarter to around108K, but are trending below its and consensus numbers. The firm keeps an Outperform rating on the stock.
News For VVUS From The Last 14 Days
Check below for free stories on VVUS the last two weeks.